Capricor Therapeutics, Inc. GAAP EPS of -$0.62 misses by $0.08, revenue of $0M
Source: SeekingAlpha
2026-03-12 16:02:56 ET
More on Capricor Therapeutics, Inc.
- Capricor Therapeutics: A High Risk/High Reward Name
- Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Trial Results and Regulatory Path for Duchenne Muscular Dystrophy Therapy Transcript
- Capricor Therapeutics, Inc. Q4 2025 Earnings Preview
- Capricor extends rally as FDA to review rejected cell therapy
- Seeking Alpha’s Quant Rating on Capricor Therapeutics, Inc.
Read the full article on Seeking Alpha
For further details see:
Capricor Therapeutics, Inc. GAAP EPS of -$0.62 misses by $0.08, revenue of $0M
Capricor Therapeutics Inc.
NASDAQ: CAPR
CAPR Trading
1.19% G/L:
$33.25 Last:
534,893 Volume:
$33.94 Open:
CAPR Latest News
March 12, 2026 04:01:00 pm
Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
CAPR Stock Data
$1,278,443,622
46,286,693
0.54%
28
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
